Drug intelligence / Profile preview

AccuVAC-D002

Development stage: Unknown
Lead developer: Defence Therapeutics
Modality: Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intradermal, Subcutaneous

Overview

**AccuVAC-D002** is an autologous dendritic cell based cancer vaccine being developed by Defence Therapeutics for melanoma. It uses the company's AccuTM intracellular delivery platform to enhance loading and cross-presentation of tumor antigens by dendritic cells, with the goal of improving activation of antigen-specific anti-tumor T-cell responses. Public descriptions indicate it was being advanced toward first-in-human clinical testing, with manufacturing activities underway and Phase I preparation for melanoma reported in the 2021 to 2022 period.

Other names: AccuVAC-D002AccuVAC-D-002AccuVAC-D 002

Beyond the preview

Go deeper on AccuVAC-D002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AccuVAC-D002.

Explore the full profile